These results were not only supportive for the reliability of this screening assay, but also consistent with the previous reports of the drugs targeting CSCs16–18 and E-cadherin-mutant cancer cells.19 We compared drug sensitivity among three types of cell lines, the GE, flat and round GC, and found that the 12 candidate drugs were subdivided into two groups, ones selectively killing both the flat and round GC cell lines (e.g., mefenamic acid, rosuvastatin, dipyridamole and NADIDE) and ones doing only the round GC (Supplementary Figure 4B). The gene discussed is CDH1; the disease is cancer.